Sitting at Work Tied to Higher Risk for Premature Death

2024-01-24

临床结果

WEDNESDAY, Jan. 24, 2024 -- Individuals who predominantly sit at work face a higher risk for all-cause and cardiovascular disease (CVD) mortality, according to a study published online Jan. 19 in JAMA Network Open.

Wayne Gao, Ph.D., from Taipei Medical University in Taiwan, and colleagues assessed whether health outcomes are associated with prolonged occupational sitting across various levels of physical activity in seemingly healthy adults. The analysis included 481,688 individuals followed for a mean 12.85 years.

The researchers found that when adjusting for sex, age, education, smoking, drinking, and body mass index, individuals who mostly sat at work had a higher all-cause mortality risk (hazard ratio [HR], 1.16; 95 percent confidence interval [CI], 1.11 to 1.20) and CVD-related mortality risk (HR, 1.34; 95 percent CI, 1.22 to 1.46) compared with those who were mostly nonsitting at work. There was no increased risk for all-cause mortality among individuals alternating sitting and nonsitting at work (HR, 1.01; 95 percent CI, 0.97 to 1.05). Participants with a personal activity intelligence score >100 experienced a reduction in the elevated mortality risk associated with prolonged occupational sitting. An increase in leisure-time physical activity (LTPA) by 15 and 30 minutes per day, respectively, for individuals mostly sitting at work and engaging in low (15 to 29 minutes per day) or no (

"Emphasizing the associated harms and suggesting workplace system changes may help society to denormalize this common behavior, similar to the process of denormalizing smoking," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Posted January 2024

More news resources

FDA Medwatch Drug Alerts

Daily MedNews

News for Health Professionals

New Drug Approvals

New Drug Applications

Drug Shortages

Clinical Trial Results

Generic Drug Approvals

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.